Close
FINDING CURES TOGETHER<sup>SM</sup>

Pancreatic Cancer: Advances in Science and Clinical Care

​Program

Friday, Sept. 21

Saturday, Sept. 22

Sunday, Sept. 23

Monday, Sept. 24

Friday, Sept. 21

Registration
3-7 p.m.


Welcome and Keynote Lectures 

6-8:10 p.m.

Welcome from Cochairs
Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Welcome from Lead Supporters
Kerri Kaplan, Lustgarten Foundation, Woodbury, New York
Lynn M. Matrisian, Pancreatic Cancer Action Network, Manhattan Beach, California

Precision medicine for pancreas cancer: New approaches from old
Ben Z. Stanger, Abramson Cancer Center of University of Pennsylvania, Philadelphia, Pennsylvania

Designing clinical trials in pancreatic cancer: Challenges and innovations

Andrew H. Ko, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

Outcomes of surveillance and treatment of high risk individuals

Marcia Irene Canto, Johns Hopkins University, Baltimore, Maryland


Opening Reception

8:15-10 p.m.

Top of page


Saturday, Sept. 22

Breakfast and Networking Roundtables
7:30-8:30 a.m.

  • Andrew Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts
  • Marcia Irene Canto, Johns Hopkins University, Baltimore, Maryland
  • Eugene Koay, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Steven D. Leach, Dartmouth Norris Cotton Cancer Center, Lebanon, New Hampshire
  • Senthil K. Muthuswamy, Beth Israel Deaconess Medical Center, Boston, Massachusetts
  • Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, Minnesota
  • Michael H. Rosenthal, Dana-Farber Cancer Institute, Boston, Massachusetts

Plenary Session 1: Imaging/Diagnostics 
8:30-10 a.m.
Session Chair: Julie L. Sutcliffe, University of California, Davis, California

Pancreas imaging 2018: MDCT, 3D rendering and deep learning
Elliot K. Fishman, Johns Hopkins Hospital, Baltimore, Maryland

Immunologic properties of biophysical subtypes of pancreatic cancer: Implications for therapeutic selection
Eugene Koay, The University of Texas MD Anderson Cancer Center, Houston, Texas

Using artificial intelligence to extract latent biomarkers from clinical imaging of the pancreas
Michael H. Rosenthal, Dana-Farber Cancer Institute, Boston, Massachusetts

Break
10-10:30 a.m.


Plenary Session 2: The Changing Practice of Genetic Testing 
10:30 a.m.-12:30 p.m.
Session Chair: Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, Minnesota

Risk estimates for pancreatic cancer predisposition genes
Fergus J. Couch, Mayo Clinic, Rochester, Minnesota

Therapeutic implications of germline variants in pancreatic cancer
Maeve Lowery, Trinity College Dublin, Dublin, Ireland

Genetic predisposition to pancreatic cancer: Who should be tested, and how?
Elena M. Stoffel, University of Michigan, Ann Arbor, Michigan

Identification and management of healthy individuals with pancreatic cancer susceptibility gene mutations
Sapna Syngal, Dana-Farber Cancer Institute, Boston, Massachusetts


Poster Session A/Lunch
12:30-3 p.m.


Plenary Session 3: Blood-Based Early Detection 
3:15-4:45 p.m.
Session Chair: Marcia Irene Canto, Johns Hopkins University, Baltimore, Maryland

Multi-analyte blood test for the detection of cancer
Nickolas Papadopoulos, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Developing a biomarker panel to detect early-stage pancreatic cancer
Kenneth S. Zaret, University of Pennsylvania, Philadelphia, Pennsylvania

Multiplex enrichment and detection of KRAS mutations in liquid biopsy samples using digital droplet pre-amplification
Erica D. Pratt, University of Minnesota, Minneapolis, Minnesota


Break
4:45-5 p.m.


Plenary Session 4: Immunology and Immunotherapy 
5-6:30 p.m.
Session Chair: Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Immunotherapy strategies in PDAC
Manuel Hidalgo

Decoding the T cell-antigen landscape of long-term pancreatic cancer survivors
Vinod Balachandran, Memorial Sloan Kettering Cancer Center, New York, New York

Innate and adaptive immunity in the tumor microenvironment of pancreas cancer
David C. Linehan, University of Rochester, Rochester, New York


Evening Off/Dinner on Own
6:30 p.m.-

Top of page


Sunday, Sept. 23

Breakfast and Networking Roundtables
7:30-8:30 a.m.

  • Andrew Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts
  • Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, New York
  • Kerri Kaplan, Lustgarten Foundation, Woodbury, New York
  • Eugene Koay, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Steven D. Leach, Dartmouth Norris Cotton Cancer Center, Lebanon, New Hampshire
  • David C. Linehan, University of Rochester, Rochester, New York
  • Senthil K. Muthuswamy, Beth Israel Deaconess Medical Center, Boston, Massachusetts
  • Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, Minnesota


Plenary Session 5: Tumor Microenvironment  
8:30-10 a.m.
Session Chair: Ronald M. Evans, Salk Institute for Biological Studies, La Jolla, California

The tumor microenvironment of primary and metastatic pancreatic adenocarcinoma: Similarities, differences, and response to treatment
Michael A. Hollingsworth, UNMC Eppley Institute for Research in Cancer, Omaha, Nebraska

Fibroblast heterogeneity in pancreatic cancer
David A. Tuveson, Cold Spring Harbor Laboratory Cancer Center, Cold Spring Harbor, New York

Exploiting the complex stromal biology of pancreas cancer
Sunil R. Hingorani, Fred Hutchinson Cancer Research Center, Seattle, Washington

Break
10-10:30 a.m.


Plenary Session 6: RAS/Signaling/Oncogenes 
10:30 a.m.-12:30 p.m.
Session Chair: Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Engineered exosomes for precision therapy of pancreatic cancer
Raghu Kalluri, The University of Texas MD Anderson Cancer Center, Houston, Texas

Treatment of oncogenic activation of ERK in human cancer
Neal Rosen, Memorial Sloan Kettering Cancer Center, New York, New York

KRas-mediated regulation of the tumor microenvironment
Ronald A. DePinho, The University of Texas MD Anderson Cancer Center, Houston, Texas

Complete regression of advanced pancreatic ductal adenocarcinomas in genetically engineered mice upon combined inhibition of EGFR and c-RAF signaling pathways
Mariano Barbacid, Spanish National Cancer Research Center, Madrid, Spain


Free Time/Lunch on Own
12:30-2:30 p.m.


Plenary Session 7: Metabolism and Metabolomics 
2:45-4:45 p.m.
Session Chair: Ronald M. Evans, Salk Institute for Biological Studies, La Jolla, California

Epigenetic control of PDA genomic networks
Ronald M. Evans

Title to be announced
Nabeel M. Bardeesy, Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Targeting cysteine metabolism in pancreatic cancer
Kenneth P. Olive, Columbia University Irving Comprehensive Cancer Center, New York, New York

Metabolic vulnerabilities – targeting oxidative phosphorylation
Giulio F. Draetta, The University of Texas MD Anderson Cancer Center, Houston, Texas


Spotlight on Proffered Papers 
5-5:40 p.m.
Session Chair: Brian M. Wolpin, Dana-Farber Cancer Institute, Boston, Massachusetts

Post translational O GlcNAcylation of SOX2 controls its tumor initiation properties in pancreatic cancer
Nikita Sharma, University of Miami, Miami, Florida

Identification of functional heterogeneity of fibroblasts and their impact on riot immunity in pancreatic cancer
Josephine Darpolor, The University of Texas MD Anderson Cancer Center, Houston, Texas

Lysyl oxidases suppress pancreatic cancer progression by inhibiting focal adhesion kinase signaling
Mario Shields, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

PDAC development and progression is dependent upon SHP2
Michael VanSaun, University of Miami, Miami, Florida

RNA profiling and the impact of current classifiers on survival in patients receiving combination chemotherapy on the COMPASS trial
Grainne O'Kane, Princess Margaret Cancer Centre, Toronto, ON, Canada


Poster Session B/Reception
5:45-8 p.m.


Evening Off/Dinner on Own
8 p.m.-

Top of page


Monday, Sept. 24

Breakfast

7:30-8:30 a.m.


Plenary Session 8: Precision Medicine 
8:30-10 a.m.
Session Chair: Steven D. Leach, Dartmouth Norris Cotton Cancer Center, Lebanon, New Hampshire

Genomic and functional subtyping of pancreatic cancer to enable precision medicine
Andrew Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts

Using pancreatic organoids to model, detect and treat cancer
Senthil K. Muthuswamy, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Mixed messages: Altered mRNA splicing provides a new therapeutic vulnerability in p53-mutant pancreatic cancer
Lusia Escobar-Hoyos, Memorial Sloan Kettering Cancer Center, New York, New York

Break
10-10:15 a.m.


Plenary Session 9: Local-Regional Therapies / Management of Local Disease 
10:15-11:45 a.m.
Session Chair: Susan Tsai, Medical College of Wisconsin, Milwaukee, Wisconsin

Pancreas SBRT: Ablation versus immune potentiation
Joseph M. Herman, The University of Texas MD Anderson Cancer Center, Houston, Texas

Why operable pancreatic cancer is the best model for translational research: Treatment sequencing, assessment of response, and results with innovative multimodality therapy
Douglas B. Evans, Medical College of Wisconsin, Milwaukee, Wisconsin

New directions in adjuvant and neoadjuvant therapy for pancreas cancer
Eileen O’Reilly, Memorial Sloan Kettering Cancer Center, New York, New York


Panel Discussion on Clinical Trials 
11:45 a.m.-12:45 p.m.
Moderator: Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, Minnesota

Panelists:
James L. Abbruzzese, Duke University Medical Center, Durham, North Carolina

Wen Wee Ma, Mayo Clinic, Rochester, Minnesota

Lynn M. Matrisian, Pancreatic Cancer Action Network, Manhattan Beach, California

Andrea Wang-Gillam, Washington University in St.Louis, St. Louis, Missouri

Diane M. Simeone, New York University, New York, New York


Departure
12:45 p.m.


Top of page